Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ISRCTN91904759) titled 'Weight reduction in asthma programme with tirzepatide' on Sept. 21.
Study Type: Interventional
Study Design:
Allocation: Randomized controlled trial
Masking: Blinded (masking used)
Control: Placebo
Assignment: Single
Purpose: Treatment, Safety
Primary Sponsor: University of East Anglia
Condition:
Asthma with obesity
Respiratory
Intervention:
Participants will be randomised, on a 1:1 ratio, to receive one of the two following treatments for 52 weeks:
Active arm:
Tirzepatide 15 mg subcutaneous injection once weekly for 32 weeks following a dose up-titration from 2.5 mg weekly every four weeks over a 20-week...